Breakdown | |||||
TTM | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 | Jun 2020 |
---|---|---|---|---|---|
Income Statement | Total Revenue | ||||
38.05M | 33.15M | 32.34M | 21.94M | 25.27M | 22.54M | Gross Profit |
17.67M | 24.37M | -2.52M | -3.06M | 16.67M | 13.74M | EBIT |
-1.17M | -16.87M | -20.27M | -15.70M | -5.24M | 1.87M | EBITDA |
-15.53M | -29.45M | -4.28M | -12.86M | -11.11M | 3.03M | Net Income Common Stockholders |
-29.74M | -40.99M | -5.61M | -12.41M | -12.56M | 379.00K |
Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
2.13M | 9.73M | 24.66M | 20.40M | 36.28M | 15.54M | Total Assets |
19.10M | 59.16M | 109.49M | 101.36M | 100.17M | 94.85M | Total Debt |
0.00 | 2.29M | 2.56M | 2.81M | 3.05M | 3.36M | Net Debt |
-2.13M | -7.45M | -22.10M | -17.59M | -33.23M | -12.19M | Total Liabilities |
1.52M | 13.43M | 28.17M | 44.06M | 31.87M | 51.51M | Stockholders Equity |
16.64M | 45.73M | 81.31M | 57.30M | 68.30M | 43.34M |
Cash Flow | Free Cash Flow | ||||
-6.79M | -13.95M | -24.16M | -15.94M | -15.37M | -8.30M | Operating Cash Flow |
-5.08M | -10.78M | -16.50M | -10.72M | -8.81M | 601.00K | Investing Cash Flow |
-2.06M | -3.17M | -7.67M | -5.21M | -6.56M | -8.90M | Financing Cash Flow |
8.69M | -807.00K | 28.06M | 142.00K | 36.12M | -1.97M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
79 Outperform | AU$56.78B | 27.93 | 25.23% | 0.85% | 10.54% | 38.69% | |
73 Outperform | $17.56B | 47.45 | 20.61% | 1.61% | 6.35% | 5.97% | |
72 Outperform | AU$12.68B | 23.17 | 6.86% | 4.05% | 10.15% | 6.20% | |
69 Neutral | $117.14B | 28.12 | 15.38% | 1.85% | 8.00% | 9.09% | |
66 Neutral | $8.65B | 1,057.58 | 0.52% | 2.23% | 7.25% | -99.04% | |
54 Neutral | $5.31B | 3.28 | -45.10% | 2.80% | 16.76% | 0.02% | |
44 Neutral | AU$69.85M | ― | -45.40% | ― | 13.61% | -55.12% |
Medical Developments International Limited announced the issuance of 2,687,635 performance rights under an employee incentive scheme. These securities are unquoted and subject to transfer restrictions, reflecting the company’s strategy to incentivize its workforce and align their interests with corporate performance, potentially impacting its operational efficiency and market positioning.
The most recent analyst rating on (AU:MVP) stock is a Buy with a A$0.80 price target. To see the full list of analyst forecasts on Medical Developments International Limited stock, see the AU:MVP Stock Forecast page.
Medical Developments International Limited announced the resignation of Richard Betts and the appointment of Paul Townsend to its Board, effective 30 May 2025. Paul Townsend, a seasoned finance leader with extensive experience across multiple sectors, will assume the role of Chair of the Audit & Risk Committee. His background in driving business outcomes and leading major organizational changes is expected to support MVP’s strategic growth objectives. The company anticipates that Townsend’s expertise will aid in unlocking its full potential and achieving long-term global growth.
The most recent analyst rating on (AU:MVP) stock is a Buy with a A$0.80 price target. To see the full list of analyst forecasts on Medical Developments International Limited stock, see the AU:MVP Stock Forecast page.
Medical Developments International Limited reported strong financial performance for Q3 FY25, with a $1.7 million operating cash flow and a cash balance of $19.1 million. The company saw increased demand for Penthrox in both the Australian hospital segment and European markets, signing a new distribution agreement with Ethypharm in France. Despite expected lower earnings in the second half of FY25 due to foreign exchange rates, the company anticipates improved full-year EBIT driven by higher Penthrox prices and operational efficiencies.
Medical Developments International Limited has announced the appointment of Mark Fladrich as a director effective April 1, 2025. The announcement, made under listing rule 3.19A.1, indicates that there are currently no relevant interests in securities or contracts associated with the new director, which suggests a straightforward transition without immediate financial implications for the company.